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Abstract 
A Rh-catalyzed ortho-amidation of 2-aryloxazolines offers an efficient and direct route to a 
range of sulfonamides. The scope of the reaction is very broad with respect to sulfonamide 
substrate, but the position and electronic nature of the substituents on the aryl moiety of the 
oxazoline lead to a surprising modulation of reactivity. The reactivity of sulfonamides in 
comparison to trifluoroacetamide is compared, the latter undergoing Rh-catalyzed amidation 
more rapidly. 
  
Introduction 
Sulfonamides represent an important functional group within organic chemistry as evidenced 
by their prevalence within natural and non-natural compounds.1 Typical synthetic approaches 
rely on the functionalization of anilines or amines with reactive sulfonyl chlorides (scheme 
1a).2 Buchwald-Hartwig cross-coupling represents a powerful and complementary C-N bond 
forming alternative (scheme 1b). However, the methodology requires the use of a pre-
functionalized coupling partner in the form of a halide/pseudo halide.3 An alternative means 
of introducing of the sulfonamide group is by C-H activation (scheme 1c). C-H activation has 
emerged as a very successful approach towards the synthesis of complex molecular 
scaffolds.4 In particular, C-H amidation protocols represent a powerful strategy for the 
formation of C(sp2)-N bonds, in which sulfonamides have been demonstrated to be successful 
coupling partners.5  
Scheme 1: N-Arylsulfonamide synthetic methods 
 
We recently disclosed an efficient and regioselective rhodium-catalyzed C-H 
amidation/cyclization sequence to afford functionalized quinazoline and quinazolinone 
derivatives.6 We also recently described the successful applicability of our methodology on 
2-substituted pyridines.7 Within our rhodium-catalyzed C-H amidation step, we chose the 
trifluoroacetamide as the amino source because of the ease of hydrolysis of this functionality. 
However, we recognized the potential of this strategy to directly deliver a range of N-aryl 
sulfonamides and report herein the scope of this process. Moreover, we highlight some 
surprising reactivity differences with regard to the substrate amine donors and aryl acceptors. 
Our investigations were inspired by Su and co-workers who demonstrated the successful Rh-
catalyzed reaction of 2-phenyl pyridines with an array of functionalized sulfonamides.8 In 
addition, a small selection of aryl oxazolines were disclosed (4 examples) that were employed 
in conjunction with para-toluenesulfonamide. Given the potential for oxazolines to be used 
as surrogates for carboxylic acid derivatives,9 we decided to fully investigate the scope of the 
oxazoline directed rhodium-catalyzed C-H amidation of aromatic compounds with aryl 
sulfonamides. 
Results and Discussion 
Our previous work had highlighted that oxazolines promote an unusually mild amidation 
reaction when trifluoroacetamide is employed; the product yields are similar when the 
reactions are conducted at 100 °C or 40 °C.6 Furthermore, the reaction was found to proceed 
quite efficiently at room temperature. We decided to carry out a similar investigation using 
para-toluenesulfonamide, in order to identify an optimal reaction temperature and to compare 
the reactivity of this amine source with trifluoroacetamide. As depicted in scheme 2, the 
reaction was found to proceed well at 100 °C affording the C-H amidated product in an 
excellent yield of 92%. In contrast to trifluoroacetamide however, lowering the temperature 
to 40 °C led to a significant drop in yield. Moreover, conducting the reaction at 25 °C 
resulted in a poor isolated yield of 22% ± highlighting the sluggish nature of this substrate at 
ambient temperature. Overall, we were interested to note that the reaction conditions required 
to afford efficient C-(sp2)N bond formation were harsher in the case of the sulfonamide 
versus trifluoroacetamide, implicating a key roOH RI WKH DPLQH GRQRU¶V UROH LQ dictating 
reactivity.  
Scheme 2: Comparative study of reaction temperature on the reactivity of 
trifluoroacetamide and para-toluenesulfonamide 
 
We next decided to investigate the nature of sulfonamides which could be used in 
conjunction with aryl oxazolines in the rhodium-promoted system (scheme 3). Pleasingly, a 
range of aromatic sulfonamides could be used alongside the gem-dimethyl oxazoline 
directing group at the optimum reaction temperature of 100 °C and only mono-aminated 
products were observed in all cases. Under the standard reaction conditions both electron 
withdrawing and electron donating functionalities were well tolerated by the sulfonamide 
group. Additionally, ortho-, meta- and para-methyl functionalized sulfonamides afforded the 
C-H amidated products in good to excellent yield. Finally, alkyl sulfonamides were found to 
be viable substrates in combination with both the unsubstituted and gem-dimethyl oxazoline 
directing group.  
Scheme 3: Sulfonamide scope 
 
We then turned our attention to the functionalities on the aryl oxazoline (scheme 4). 
Pleasingly under the optimum reaction conditions, we found a small selection of 
electronically distinct aryl oxazolines were well tolerated. Both electron poor and electron 
rich aryl systems were successful, as demonstrated by the methoxy- and trifluoromethyl-
substituted examples (12 and 13).  
Scheme 4: Oxazoline scope 
 In an effort to demonstrate utility of this particular transformation we targeted the synthesis 
of sulfonamide 16, a known potassium ion channel inhibitor.10 We envisaged that the 
employment of our optimal C-H amidation conditions for sulfonamides would readily deliver 
16 from 3-methoxy substituted aryl oxazoline 15 and 3-(trifluoromethyl)benzenesulfonamide 
(scheme 5). In the event, we were surprised to find that this reaction failed to proceed, even 
after heating over an extended time period. In order to rule out the sulfonamide as the source 
of low reactivity, 3-(trifluoromethyl)benzenesulfonamide was reacted with 2-phenyl 
oxazoline 17. This reaction proceeded smoothly to afford the corresponding product 18 in an 
excellent yield of 83%. We next decided to further examine the reactivity of 3-methoxy 
substituted aryl oxazoline 15 by subjecting it to our standard reaction conditions with 
trifluoroacetamide. Interestingly, in this case we observed only a poor yield of 20% of 
product 19. Finally, 4-methoxyphenyl oxazoline 20 was found to show good reactivity 
towards 3-(trifluoromethyl)benzenesulfonamide, affording compound 21 in 62% yield. Taken 
together, these results indicated that the C-H amidation reaction could be retarded by the 
presence of an electron donating substituent situated meta to the oxazoline directing group. 
Scheme 5: Initial investigations into the effect of electron donating groups on oxazoline 
reactivity 
 In order to explore the generality of this observation, an array of para- and meta-substituted 
aryl oxazolines bearing both electron donating and electron withdrawing functionalities were 
prepared. For the purpose of comparison, each substrate was subjected to the optimum 
reaction conditions with para-toluenesulfonamide at 100 °C and trifluoroacetamide at 40 °C. 
As shown in scheme 6 and in a similar manner to above, the incorporation of an electron 
donating methoxy group para- to the oxazoline was highly successful with both amino 
sources delivering the corresponding products in high yield. In contrast, when the methoxy 
group was meta- to the directing group the reaction was significantly retarded. These data 
clearly show that the positioning of the functional group can have a profound effect on 
reactivity. Next, the reactivity of methyl substituted oxazolines was investigated. We 
observed better overall reactivity in these cases, however, the combination of a meta-methyl 
group and the less reactive sulfonamide resulted in product 29 being generated in rather 
modest yield. Switching to an electron withdrawing ester substituent, we were interested to 
note that both para- and meta-functionalized examples afforded similar reaction outcomes. 
Both substrates were reactive and the desired compounds were isolated in good yields. 
Finally, we wanted to explore the effect of a fluorine group on the C-H amidation reaction. In 
this series, the para-functionalized example produced the C-H amidated products with both 
amino sources in good to excellent yield. However, in the case of the meta-functionalized 
example, we observed insertion at the more hindered position between the oxazoline and the 
fluoride. This regioselectivity was surprising as we had not observed the analogous 
regiochemical C-H insertion in any of our other meta-substituted examples. The outcome was 
independent of amine source and both para-toluenesulfonamide and trifluoroacetamide 
inserted into the 2-position of the aryl ring with high selectivity and yield. The structure of 
the C-H amination product arising from the reaction between 3-fluro substituted oxazoline 
and para-toluenesulfonamide was unambiguously confirmed by X-ray crystallography.11 
Notably, selective insertion into the 2-position of similar meta-fluoro scaffolds by C-H 
activation methodologies has received only scant precedent. Reports by Sanford and others 
demonstrated insertion into the 6-position under palladium-catalyzed C-H activation.12 A 
single report by Yu described a mixture of insertion products (1:1.5 C2:C6) when N-(2-(4,5-
dihydrooxazol-2-yl)phenyl)-2-fluorobenzamide is subjected to C-H amidation conditions 
with stoichiometric Cu(OAc)2 and para-toluenesulfonamide.13  
Scheme 6: Comparative study of meta-substituted versus para-substituted substrates 
 We were interested to note that in all of the cases examined the trifluoroacetamide is superior 
to that of the sulfonamide, both in terms of milder conditions and higher yield. The reactivity 
and selectivity trends observed in the C-H amidation of various aromatic oxazolines with 
trifluoroacetamide and sulfonamides is intriguing, and our observations highlight some 
unexpected trends. In particular, we felt that the low reactivity observed in the cases of 
dimethylamino-functionalized aromatics, and the meta-methoxy aromatic substrates, together 
with the unusual regioselectivity observed with the meta-fluoro substrate were particularly 
intriguing and warranted further investigation. Accordingly, we decided to conduct deuterium 
labelling experiments and these are shown in Scheme 7.8,14 We conducted the reaction 
between 3-methoxy aryloxazoline 15 and para-toluenesulfonamide in the presence of 
deuterated methanol, and observed 74% mass recovery. The mixture did not contain 
amidation product, but we observed almost quantitative deuterium incorporation affording a 
mixture of mono- and di-deuterated materials 39 and 40. This result confirms that rhodacycle 
formation proceeds under the reaction conditions, but suggests that the problematic step in 
the catalytic cycle is related to the formation of Rh(V)-nitrenoid species B. Although the 
origin of this effect await further study, it may be that the presence of an electron donating 
meta-substituent (with respect to the directing group) results in a strengthening the carbon-
rhodium bond in rhodacycle A retarding nitrene insertion, or that strong electron donation 
reduces the propensity for formation of Rh-nitrenoid intermediates. In addition, running the 
same reaction of 3-dimethylamino aryl oxazoline 41 resulted in <5% deuterium incorporation 
(as judged by 400 MHz 1H NMR spectroscopy) and only recovery of the starting material, 
suggesting that slow cyclometallation is occurring in this case.  Finally, carrying out the 
deuterium labelling experiment with the meta-fluoro aryloxazoline we were able to observe a 
mixture which contained C-H amidation product 37 and a 1:1 mixture of recovered starting 
material and mono C2 deuterated starting material. The observation of C2-selective mono 
deuteration indicated that it is likely that selective rhodacycle formation gives rise to the 
observed product, rather than product determining nitrene insertion. We believe the selective 
rhodacycle formation is a result of the enhanced acidity of the proton ortho to the fluoro 
substituent.  
Scheme 7: Deuterium incorporation studies and abbreviated mechanism 
 Finally, in order to show the potential of this method for synthesis of functionalized scaffolds 
we targeted the C-H amidation of 2-chloropyridine 44 (scheme 8). This substrate underwent 
smooth amidation and in high regiocontrol to generate 45.7 Subsequent hydrolysis of the 
acetamide followed by the oxazoline delivered aza-anthranilic ester 46 in acceptable overall 
yield. 
Scheme 8: Synthesis of multi-functionalized heterocycles 
 In conclusion, we have described the extension of our rhodium-promoted C-H amidation 
conditions to sulfonamide amino sources. We found a reaction temperature of 100 °C was 
key to affording efficient amidation with a range of aryl and alkyl sulfonamides, and that a 
range of functionalized oxazoline scaffolds were well tolerated. Through investigation and 
comparative study, we found aryl oxazolines with electron donating meta-substituents were 
incompatible with the reaction system whilst their para-substituted counterparts were highly 
successful. Mechanistic studies suggested this could be due to the inhibition of the formation 
of key Rh(V)-nitrenoid species, or a slow nitrene insertion step. Additionally, we observed 
the opposite regioselectivity of amide insertion with 3-fluoro aryloxazoline and determined 
this observation to be the result of regioselective rhodacycle formation.  
Experimental Section 
The following substrates were prepared according to a previously reported procedures 2-(p-
tolyl)-4,5-dihydrooxazole6, 2-(4-methoxyphenyl)-4,5-dihydrooxazole (20)6, 2-(4-
trifluoromethylphenyl)-4,5-dihydrooxazole6, 2-(4-bromophenyl)-4,5-dihydrooxazole6, 2-(m-
tolyl)-4,5-dihydrooxazole6, 2-(4-fluorophenyl)-4,5-dihydrooxazole6, methyl 3-(4,5-
dihydrooxazol-2-yl)benzoate6 and 2-(2-chloropyridin-4-yl)-4,5-dihydrooxazole (44).7 
General procedure A: Amide Synthesis. To a dried round bottomed flask was added ester (1.0 
eq.) and heated to 55 °C with stirring. Upon reaching the desired temperature ethanolamine 
(1.5 eq.) was added slowly via syringe and the reaction was stirred for 3 h before cooling to 
room temperature, and stirring for a further 18 hours. The crude reaction mixture was then 
purified by recrystallisation or flash column chromatography on silica gel eluting with 
dichloromethane and methanol (1% MeOH to 20% MeOH) or ethyl acetate (100%) to afford 
the amide products.  
Synthesis of N-(2-hydroxyethyl)-3-methoxybenzamide15. Following general procedure A, 
using ethyl 3-methoxybenzoate (3.09 g, 17.2 mmol) and ethanolamine (1.57 g, 25.8 mmol) 
the amide product was afforded as a yellow oil (3.18 g, 95%). 1H NMR
 
(400 MHz, CDCl3į
7.35 (1H, s), 7.29 (2H, dd, J = 4.0, 2.5 Hz), 7.05 ± 6.93 (2H, m), 3.82 ± 3.77 (5H, m), 3.58 
(2H, app dd, J = 10.0, 5.0 Hz); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
129.7, 119.0, 117.9, 112.5, 62.2, 55.5, 43.0. 
 Synthesis of 3-fluoro-N-(2-hydroxyethyl)benzamide16. Following general procedure A, using 
ethyl 3-fluorobenzoate (2.29 g, 13.6 mmol) and ethanolamine (1.25 g, 20.4 mmol) the amide 
product was afforded as a yellow oil (1.62 g, 65%). 1H NMR
 
(400 MHz, DMSO-d6į
(1H, s), 7.74 ± 7.68 (1H, m), 7.65 (1H, ddd, J = 10.0, 2.5, 1.5 Hz), 7.51 (1H, td, J = 8.0, 6.0 
Hz), 7.42 ± 7.32 (1H, m), 3.51 (2H, q, J = 6.0 Hz), 3.33 (2H, q, J = 6.0 Hz); 13C{1H} NMR
 
(100.6 MHz, DMSO-d6įGJ = 2.0 Hz), 161.9 (d, J = 244.0 Hz), 136.9 (d, J = 6.5 
Hz), 130.4 (d, J = 8.0 Hz), 123.3 (d, J = 2.5 Hz), 117.9 (d, J = 21.0 Hz), 114.0 (d, J = 22.5 
Hz), 59.6, 42.3; 19F NMR
 
(376.5 MHz, DMSO-d6į± 113.0. 
General procedure B: Amide Synthesis. To a stirred solution of benzoic acid (1.0 eq.) in dry 
dichloromethane (0.2 M) at 0 °C was added oxalyl chloride (3.0 eq.) and DMF (few drops). 
The reaction was allowed to warm to room temperature and stirred for a period of 3 hours 
before removing the solvent in vacuo. The crude residue was then dissolved in dry 
dichloromethane (0.2 M) and cooled to 0 °C using an ice bath. Triethylamine (3.0 eq.) was 
then added, followed by ethanolamine (3.0 eq.) via syringe. The reaction was allowed to 
warm to room temperature and stir overnight. The reaction mixture was then dry loaded onto 
silica gel and purified by flash column chromatography on silica gel eluting with 
dichloromethane and methanol (0 to 10% MeOH) to afford the amide products. 
Synthesis of 4-(dimethylamino)-N-(2-hydroxyethyl)benzamide. Following general procedure 
B, using 4-dimethylaminobenzoic acid (1.00 g, 6.05 mmol), oxalyl chloride (2.31 g, 18.2 
mmol) and DMF (few drops) in dichloromethane (30 mL), then ethanolamine (1.11 g, 18.2 
mmol), triethylamine (1.84 g, 18.2 mmol) and dichloromethane (30 mL) the amide product 
was afforded as a colorless amorphous solid (763 mg, 61%). FTIR: vmax/ cm-1 (neat) 3362 
(m), 2943 (w), 2871 (w), 1609 (m), 1521 (m), 1205 (m), 1056 (m); 1H NMR
 
(400 MHz, 
MeOD-d4į± 7.50 (2H, m), 6.93 ± 6.52 (2H, m), 3.69 (2H, t, J = 6.0 Hz), 3.48 (2H, t, J 
= 6.0 Hz), 3.00 (6H, s); 13C{1H} NMR
 
(100.6 MHz, MeOD-d4į 
112.1, 61.9, 43.4, 40.2; HRMS: m/z [MH]+ C11H17N2O2 calcd. 209.1285, found 209.1288. 
Synthesis of 3-(dimethylamino)-N-(2-hydroxyethyl)benzamide. Following general procedure 
B, using 3-dimethylaminobenzoic acid (1.00 g, 6.05 mmol), oxalyl chloride (2.31 g, 18.2 
mmol) and DMF (few drops) in dichloromethane (30 mL), then ethanolamine (1.11 g, 18.2 
mmol), triethylamine (1.84 g, 18.2 mmol) and dichloromethane (30 mL) the amide product 
was afforded as a yellow oil (626 mg, 50%). FTIR: vmax/ cm-1 (neat) 2807 (w), 1636 (m), 
1598 (m), 1350 (m), 1055 (s), 994 (s); 1H NMR
 
(400 MHz, CDCl3į± 7.22 (2H, m), 
7.02 (1H, d, J = 8.0 Hz), 6.87 (1H, d, J = 8.0, 2.5 Hz), 6.68 (1H, br s), 3.85 ± 3.80 (2H, app 
m), 3.62 (2H, app dd, J = 10.0, 5.5 Hz), 2.99 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
169.6, 150.6, 135.2, 129.4, 115.8, 114.7, 111.7, 62.8, 43.2, 40.9; HRMS: m/z [MH]+ 
C11H17N2O2 calcd. 209.1285, found 209.1286. 
Synthesis of methyl 4-((2-hydroxyethyl)carbamoyl)benzoate. Following general procedure B, 
using 4-(methoxycarbonyl)benzoic acid (1.00 g, 5.55 mmol), oxalyl chloride (2.11 g, 16.6 
mmol) and DMF (few drops) in dichloromethane (28 mL), then ethanolamine (1.01 g, 16.7 
mmol), triethylamine (1.68 g, 16.7 mmol) and dichloromethane (28 mL) the amide product 
was afforded as a colorless amorphous solid (820 mg, 66%). FTIR: vmax/ cm-1 (neat) 3330 
(w), 3287 (w), 1714 (m), 1633 (m), 1550 (m), 1283 (s), 1111 (s), 1052 (s); 1H NMR
 
(400 
MHz, MeOD-d4į± 8.07 (2H, m), 7.94 ± 7.90 (2H, m), 3.93 (3H, s), 3.72 (2H, t, J = 
6.0 Hz), 3.52 (2H, t, J = 6.0 Hz); 13C{1H} NMR
 
(100.6 MHz, MeOD-d4 į  
139.9, 133.9, 130.6, 128.5, 61.5, 52.9, 43.7; HRMS: m/z [MH]+ C11H14NO4 calcd. 224.0917, 
found 224.0920. 
General procedure C: Oxazoline Synthesis. To a dried round bottomed flask was added 
amide (1.0 eq.) and dry dichloromethane (0.6 M). With stirring NEt3 (1.9 eq.) was then 
added, followed by DMAP (0.2 eq.) and p-TsCl (1.7 eq.). The reaction mixture was allowed 
to stir at room temperature overnight, before being diluted with dichloromethane and water. 
The mixture was then transferred to a separating funnel and the layers partitioned. The 
aqueous layer was further extracted with dichloromethane. The combined organic layers were 
dried over anhydrous MgSO4, filtered and the solvent was removed in vacuo. The crude 
residue was dissolved in MeOH (0.5 M) and NaOH pellets (3.0 eq.) were added in one 
portion. The reaction mixture was stirred at room temperature for 1 ± 3 h before removing the 
solvent in vacuo. The residue was dissolved in dichloromethane and water, and transferred to 
a separating funnel. The layers were partitioned and the aqueous layer was further extracted 
with dichloromethane and ethyl acetate. The combined organic layers were dried over 
anhydrous MgSO4, filtered and the solvent was removed in vacuo. The residue was purified 
by flash column chromatography on silica gel eluting with petroleum ether (40/60) and ethyl 
acetate (0% ethyl acetate to 100% ethyl acetate) to afford the oxazoline products. 
Synthesis of 4-(4,5-dihydrooxazol-2-yl)-N,N-dimethylaniline. Following general procedure C, 
using 4-(dimethylamino)-N-(2-hydroxyethyl)benzamide (690 mg, 3.31 mmol), p-TsCl (1.07 
g, 5.63 mmol), NEt3 (636 mg, 6.29 mmol), DMAP (81 mg, 0.66 mmol) and dichloromethane 
(5.5 mL), then using NaOH pellets (400 mg, 9.93 mmol) and MeOH (6.6 mL), the oxazoline 
product was afforded as a colorless amorphous solid (347 mg, 55%). FTIR: vmax/ cm-1 (neat) 
2970 (w), 1641 (m), 1603 (s), 1530 (m), 1354 (m), 1324 (m), 1187 (s), 1159 (s), 1066 (s); 1H 
NMR
 
(400 MHz, CDCl3į± 7.73 (2H, m), 6.64 ± 6.58 (2H, m), 4.30 (2H, t, J = 9.5 
Hz), 3.94 (1H, t, J = 9.5 Hz), 2.94 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3 į 
152.1, 129.4, 114.8, 111.0, 67.1, 54.6, 40.0; HRMS: m/z [MH]+ C11H15N2O calcd. 191.1179, 
found 191.1180.  
Synthesis of 3-(4,5-dihydrooxazol-2-yl)-N,N-dimethylaniline (41). Following general 
procedure C, using 3-(dimethylamino)-N-(2-hydroxyethyl)benzamide (577 mg, 2.77 mmol), 
p-TsCl (898 mg, 4.71 mmol), NEt3 (532 mg, 5.26 mmol), DMAP (68 mg, 0.55 mmol) and 
dichloromethane (5.0 mL), then using NaOH pellets (332 mg, 8.31 mmol) and MeOH (6.0 
mL), the oxazoline product 41 was afforded as a colorless amorphous solid (272 mg, 52%). 
FTIR: vmax/ cm-1 (neat) 2977 (w), 1646 (m), 1591 (s), 1496 (s), 1433 (s), 1367 (s), 1350 (s), 
1253 (s), 1238 (s), 1066 (s); 1H NMR
 
(400 MHz, CDCl3į± 7.33 (1H, m), 7.32 ± 7.27 
(2H, m), 6.86 (1H, dt, J = 7.0, 2.5 Hz), 4.44 (2H, t, J = 9.5 Hz), 4.07 (2H, t, J = 9.5 Hz), 3.00 
(6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3 į      
112.0, 67.6, 54.9, 40.7; HRMS: m/z [MH]+ C11H15N2O calcd. 191.1179, found 191.1180. 
Synthesis of 2-(3-methoxyphenyl)-4,5-dihydrooxazole (15)17. Following general procedure C, 
using N-(2-hydroxyethyl)-3-methoxybenzamide (1.00 g, 5.12 mmol), p-TsCl (1.66 g, 8.71 
mmol), NEt3 (984 mg, 1.36 mmol), DMAP (125 mg, 1.02 mmol) and dichloromethane (8.5 
mL), then using NaOH pellets (614 mg, 15.4 mmol) and MeOH (10.2 mL), the oxazoline 
product 15 was afforded as a colorless solid (572 mg, 63%). M.p.: 60 ± 61 °C (lit., 59 ± 60 
°C)4; 1H NMR
 
(400 MHz, CDCl3į± 7.45 (1H, m), 7.43 (1H, dd, J = 2.5, 1.5 Hz), 7.24 
(1H, t, J = 8.0 Hz), 6.95 (1H, ddd, J = 8.0, 2.5, 1.0 Hz), 4.33 (2H, t, J = 9.5 Hz), 3.97 (2H, t, J 
= 9.5 Hz), 3.76 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
120.5, 117.9, 112.5, 67.6, 55.3, 54.8.   
Synthesis of 2-(3-fluorophenyl)-4,5-dihydrooxazole (42). Following general procedure C, 
using 3-fluoro-N-(2-hydroxyethyl)benzamide (1.00 g, 5.46 mmol), p-TsCl (1.77 g, 9.28 
mmol), NEt3 (1.05 g, 10.4 mmol), DMAP (133 mg, 1.09 mmol) and dichloromethane (9.1 
mL), then using NaOH pellets (655 mg, 16.4 mmol) and MeOH (11 mL), the oxazoline 
product 42 was afforded as a yellow oil (688 mg, 76%). FTIR: vmax/ cm-1 (neat) 2991 (w), 
2912 (w), 1649 (m), 1585 (s), 1270 (s), 1185 (s), 1055 (s), 949 (s), 842 (s), 715 (s); 1H NMR
 
(400 MHz, CDCl3į+GJ = 8.0 Hz), 7.65 ± 7.58 (1H, m), 7.35 (1H, td, J = 8.0, 5.5 
Hz), 7.14 (1H, td, J = 8.5, 2.5 Hz), 4.41 (2H, t, J = 9.5 Hz), 4.04 (2H, t, J = 9.5 Hz); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3įGJ = 3.0 Hz), 162.6 (d, J = 246.0 Hz), 130.0 (d, J = 8.0 
Hz), 124.0 (d, J = 3.0 Hz), 118.3 (d, J = 21.0 Hz), 115.3 (d, J = 23.5 Hz), 67.9, 55.0; 19F 
NMR
 
(376.5 MHz, CDCl3į± 112.7; HRMS: m/z [MH]+ C9H9FNO calcd. 166.0663, found 
166.0664. 
Synthesis of methyl 4-(4,5-dihydrooxazol-2-yl)benzoate18. Following general procedure C, 
using methyl 4-((2-hydroxyethyl)carbamoyl)benzoate (650 mg, 2.91 mmol), p-TsCl (945 mg, 
4.95 mmol), NEt3 (559 mg, 5.53 mmol), DMAP (71 mg, 0.58 mmol) and dichloromethane (5 
mL), then using NaOH pellets (116 mg, 6.42 mmol)  and MeOH (6 mL), the oxazoline 
product was afforded as a colorless amorphous solid (409 mg, 68%). 1H NMR
 
(400 MHz, 
CDCl3į± 8.01 (2H, m), 8.00 ± 7.93 (2H, m), 4.42 (2H, t, J = 9.5 Hz), 4.05 (2H, t, J = 
9.5 Hz), 3.89 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3 į    
129.6, 128.2, 67.9, 55.2, 52.4. 
General procedure D: C-H Amidation. To a dried Schlenk tube was added oxazoline (2.0 
eq.), [Cp*RhCl2]2 (2.5 mol %), AgSbF6 (10 mol %), PhI(OAc)2 (1.5 eq.) and sulfonamide 
(1.0 eq.). The tube was fitted with a rubber septum, and placed under an atmosphere of 
nitrogen, followed by the addition of dry dichloromethane via syringe (0.1 M). The septum 
was replaced by a Teflon screwcap under nitrogen flow. The reaction mixture was stirred at 
40 ± 45 °C for 18 h. After cooling to room temperature the solvent was removed in vacuo and 
the residue was purified by flash column chromatography on silica gel eluting with petroleum 
ether (40/60) followed by dichloromethane or petroleum ether (40/60) and ethyl acetate (0% 
ethyl acetate to 40% ethyl acteate) to afford the aminated products. 
Synthesis of 2,2,2-trifluoro-N-[2-(4,5-dihydro-2-oxazolyl)phenyl]-acetamide (1)6. Following 
general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 2-phenyl-2-oxazoline 
(59 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and 
PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 40 °C for 16 h, product 1 was 
isolated as a colorless solid (48 mg, 92%).  M.p.: 74 ± 75 °C (pentane); FTIR: vmax/ cm-1 
(neat) 3054 (w), 2915 (w), 1734 (s), 1260 (s); 1H NMR
 
(400 MHz, CDCl3į+V
8.68 (1H, dd, J = 8.5 and 1.0 Hz), 7.90 (1H, dd, J = 8.5 and 1.0 Hz), 7.52 (1H, t, J = 8.5 Hz), 
7.21 (1H, t, J = 8.5 Hz), 4.43 (2H, t, J = 9.5 Hz), 4.16 (2H, t, J = 9.5 Hz); 13C{1H} NMR
 
(100.6 MHz, CDCl3 į   T J = 37.5 Hz), 137.7, 132.9, 129.4, 124.5, 120.3, 
116.1 (q, J = 288.5 Hz), 114.5, 66.8, 54.5; 19F NMR
 
(376.5 MHz, CDCl3į± 76.0; HRMS: 
m/z [MH]+ C11H10N2O2F3 calcd. 259.0694, found 259.0704.  
Synthesis of N-[2-(4,5-dihydro-2-oxazolyl)phenyl]-4-methyl-benzenesulfonamide (2)8. 
Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 2-
phenyl-2-oxazoline (59 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 
mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 100 °C for 
16 h, product 2 was isolated as a colorless solid (58 mg, 92%). M.p.: 191 ± 193 °C (lit.,19 195 
± 199 °C); 1H NMR
 
(400 MHz, CDCl3į+V± 7.70 (3H, m), 7.64 (1H, dd, J 
= 8.0 and 1.0 Hz), 7.37 ± 7.29 (1H, m), 7.20 (2H, d, J = 8.0 Hz), 6.99 (1H, td, J = 8.0 and 1.0 
Hz), 4.39 ± 4.31 (2H, m), 4.16 ± 4.08 (2H, m), 2.34 (3H, s); 13C{1H} NMR
 
(100.6 MHz, 
CDCl3į
54.5, 21.5. 
Synthesis of N-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]-4-methoxy-
benzenesulfonamide (3). Following general procedure D, using 4-methoxybenzene 
sulfonamide (37 mg, 0.20 mmol) and 4,4-dimethyl-2-phenyl-2-oxazoline (70 mg, 0.40 mmol) 
with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 
0.30 mmol)
 
in dichloromethane (2 mL) at 100 °C for 16 h, product 3 was isolated as a 
colorless solid (46 mg, 64%).  M.p.: 106 ± 108 °C (dichloromethane/petroleum ether 
(40/60)); FTIR: vmax/ cm-1 (neat) 2974 (w), 2849 (w), 1336 (s), 1157 (s); 1H NMR (400 MHz, 
CDCl3į+V± 7.68 (4H, m), 7.39 ± 7.31 (1H, m), 7.04 ± 6.97 (1H, m), 6.87 
± 6.80 (2H, m), 4.02 (2H, s), 3.79 (3H, s), 1.40 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3): 
į
28.6; HRMS: m/z [MH]+ C18H21N2O4S calcd. 361.1222, found 361.1237.  
Synthesis of N-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]-4-bromo-
benzenesulfonamide (4). Following general procedure D, using 4-bromobenzene sulfonamide 
(47 mg, 0.20 mmol) and 4,4-dimethyl-2-phenyl-2-oxazoline (70 mg, 0.40 mmol) with 
[Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 
mmol)
 
in dichloromethane (2 mL) at 100 °C for 16 h, product 4 was isolated as a colorless 
solid (59 mg, 72%). M.p.: 111 ± 114 °C (dichloromethane/petroleum ether (40/60)); FTIR: 
vmax/ cm-1 (neat) 3099 (w), 2961 (w), 2890 (w), 1336 (s), 1160 (s), 1064 (s); 1H NMR (400 
MHz, CDCl3į+V± 7.65 (4H, m), 7.55 ± 7.49 (2H, m), 7.41 ± 7.34 (1H, m), 
7.08 ± 7.01 (1H, m), 4.03 (2H, s), 1.39 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
139.0, 138.8, 132.5, 132.2, 129.5, 128.8, 127.7, 123.2, 118.8, 114.5, 78.2, 68.1, 28.6; HRMS: 
m/z [MH]+ C17H18N2O3S79Br calcd. 409.0222, found 409.0216.  
Synthesis of N-(2-(4,4-dimethyl-1,5-dihydrooxazol-2-yl)phenyl)-4-
(trifluoromethyl)benzenesulfonamide (5). Following general procedure D, using 4-
trifluoromethylbenzene sulfonamide (45 mg, 0.20 mmol) and 4,4-dimethyl-2-phenyl-2-
oxazoline (70 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 
mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 100 °C for 16 h, 
product 5 was isolated as a colorless solid (46 mg, 76%). M.p.: 80 ± 81 °C 
(dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 2980 (w), 1628 (m), 1506 
(m), 1340 (m), 1321 (s), 1161 (s), 1129 (s), 1059 (s); 1H NMR
 
(400 MHz, CDCl3į
(1H, s), 7.94 (2H, d, J = 8.0 Hz), 7.77 ± 7.72 (2H, m), 7.65 (2H, d, J = 8.0 Hz), 7.39 (1H, 
ddd, J = 8.5, 7.5, 1.5 Hz), 7.06 (1H, td, J = 8.0, 1.0 Hz), 4.03 (2H, s), 1.39 (6H, s); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3 į     T J = 33.0 Hz), 132.6, 129.5, 
127.7, 126.1 (q, J = 3.5 Hz), 123.4, 123.3 (q, J = 273.0 Hz), 118.9, 114.5, 78.2, 68.1, 28.6; 
19F NMR (376.5 MHz; CDCl3 į ± 63.1; HRMS: m/z [MH]+ C18H18N2O3F3S calcd. 
399.0990, found 399.0986. 
Synthesis of N-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]-4-methyl-
benzenesulfonamide (6)8. Following general procedure D, using p-toluenesulfonamide (34 
mg, 0.20 mmol) and 4,4-dimethyl-2-phenyl-2-oxazoline (70 mg, 0.40 mmol) with 
[Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 
mmol)
 
in dichloromethane (2 mL) at 100 °C for 16 h, product 6 was isolated as a colorless 
solid (43 mg, 62%). M.p.: 104 ± 106 °C (dichloromethane/petroleum ether (40/60)); 1H NMR
 
(400 MHz, CDCl3į+V+P± 7.31 (1H, m), 7.17 (2H, d, J = 8.5 
Hz), 7.07 ± 6.96 (1H, m), 4.02 (2H, s), 2.33 (3H, s), 1.42 (6H, s); 13C{1H} NMR
 
(100.6 MHz, 
CDCl3į78.1, 
68.1, 28.6, 21.6. 
Synthesis of N-(2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-3-methylbenzenesulfonamide 
(7). Following general procedure D, using 3-methylbenzene sulfonamide (39 mg, 0.20 mmol) 
and 4,4-dimethyl-2-phenyl-2-oxazoline (70 mg, 0.20 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 7 was isolated as a colorless solid (49 mg, 71%). M.p.: 98 ± 
99 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 2971 (w), 1631 
(m), 1500 (m), 1340 (s), 1280 (m), 1161 (s), 1062 (s); 1H NMR
 
(400 MHz, CDCl3į
(1H, s), 7.76 ± 7.69 (2H, m), 7.65 ± 7.63 (1H, m), 7.62 ± 7.59 (1H, m), 7.36 (1H, ddd, J = 8.5, 
7.5, 1.5 Hz), 7.29 ± 7.23 (2H, m), 7.01 (1H, ddd, J = 8.5, 7.5, 1.0 Hz), 4.02 (2H, s), 2.32 (3H, 
s), 1.39 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3 į     
132.4, 129.3, 128.7, 127.5, 124.4, 122.8, 118.8, 114.4, 78.1, 68.1, 28.6, 21.4; HRMS: m/z 
[MH]+ C18H21N2O3S calcd. 345.1273, found 345.1288. 
Synthesis of N-(2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-2-methylbenzenesulfonamide 
(8). Following general procedure D, using 2-methylbenzene sulfonamide (34 mg, 0.20 mmol) 
and 4,4-dimethyl-2-phenyl-2-oxazoline (70 mg, 0.20 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 8 was isolated as a colorless solid (57 mg, 83%). M.p.: 96 ± 
97 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 2967 (w), 1631 
(m), 1500 (m), 1337 (s), 1270 (s), 1158 (s), 1136 (s), 1056 (s), 1043 (s); 1H NMR
 
(400 MHz, 
CDCl3į+V+GGJ = 8.0, 1.5 Hz), 7.74 (1H, dd, J = 8.0, 1.5 Hz), 7.56 
(1H, dd, J = 8.5, 1.0 Hz), 7.39 (1H, td, J = 7.5, 1.5 Hz), 7.33 ± 7.24 (2H, m), 7.21 (1H, d, J = 
7.5 Hz), 6.95 (1H, ddd, J = 8.5, 7.5, 1.0 Hz), 4.06 (2H, s), 2.66 (3H, s), 1.41 (6H, s); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3į
126.0, 121.8, 116.3, 112.8, 78.1, 68.1, 28.6, 20.2; HRMS: m/z [MH]+ C18H21N2O3S calcd. 
345.1273, found 345.1270.  
Synthesis of N-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)phenyl]-4-methanesulfonamide (9). 
Following general procedure D, using methane sulfonamide (19 mg, 0.20 mmol) and 4,4-
dimethyl-2-phenyl-2-oxazoline (70 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), 
AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 
100 °C for 16 h, product 9 was isolated as a colorless solid (46 mg, 86%). M.p.: 86 ± 88 °C 
(dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 2971 (w), 2872 (w), 1322 
(m), 1142 (s), 1047 (s); 1H NMR
 
(400 MHz, CDCl3į+V+GGJ = 8.0 
and 1.5 Hz), 7.72 (1H, dd, J = 8.5 and 1.0 Hz), 7.50 ± 7.40 (1H, m), 7.16 ± 7.06 (1H, m), 4.07 
(2H, s), 3.01 (3H, s), 1.39 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
129.7, 122.8, 118.1, 114.1, 78.2, 68.1, 39.9, 28.6; HRMS: m/z [MH]+ C12H17N2O3S calcd. 
269.0960, found 269.0959. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)phenyl)methanesulfonamide (10). Following 
general procedure D, using methane sulfonamide (19 mg, 0.20 mmol) and 2-phenyl-2-
oxazoline (59 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 
mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 100 °C for 16 h, 
product 10 was isolated as a colorless solid (31 mg, 64%). M.p.: 149 ± 150 °C 
(dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 1634 (m), 1583 (m), 1494 
(m), 1319 (s), 1251 (s), 1142 (s), 1055 (s); 1H NMR
 
(400 MHz, CDCl3į+V
(1H, dd, J = 8.0, 1.5 Hz), 7.75 (1H, dd, J = 8.5, 1.0 Hz), 7.52 ± 7.43 (1H, app m), 7.13 (1H, 
td, J = 8.0, 1.0 Hz), 4.42 (2H, t, J = 9.5 Hz), 4.15 (2H, t, J = 9.5 Hz), 3.05 (3H, s); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3 į   32.9, 129.9, 122.6, 117.4, 113.6, 66.7, 54.6, 
40.0; HRMS: m/z [MH]+ C10H13N2O3S calcd. 241.0641, found 241.0647. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-5-methylphenyl)-4-methylbenzenesulfonamide 
(11)8. Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 
2-(p-tolyl)-4,5-dihydrooxazole (65 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), 
AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 
100 °C for 16 h, product 11 was isolated as a colorless solid (52 mg, 78%). M.p.: 117 ±118 
°C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 2950 (w), 1641 (m), 
1591 (m), 1507 (m), 1360 (m), 1324 (s), 1263 (s), 1149 (s), 1058 (s); 1H NMR
 
(400 MHz, 
CDCl3į+V+GJ = 8.0 Hz), 7.60 (1H, d, J = 8.0 Hz), 7.47 (1H, s), 7.20 
(2H, d, J = 8.0 Hz), 6.80 (1H, dd, J = 8.0, 1.0 Hz), 4.32 (2H, t, J = 9.5 Hz), 4.10 (2H, t, J = 
9.5 Hz), 2.34 (3H, s), 2.30 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3): į  
143.3, 139.1, 137.1, 129.6, 129.2, 127.3, 123.4, 118.5, 111.2, 66.5, 54.5, 22.0, 21.6; HRMS: 
m/z [MH]+ C17H19N2O3S calcd. 331.1111, found 331.1117. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-5-methoxyphenyl)-4-methylbenzenesulfonamide 
(12). Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 2-
(4-methoxyphenyl)-4,5-dihydrooxazole (71 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 12 was isolated as a colorless oil (50 mg, 72%). FTIR: vmax/ 
cm-1 (neat) 2970 (w), 1633 (s), 1606 (m), 1573 (s), 1512 (s), 1333 (s), 1142 (s), 1067 (s), 
1036 (s); 1H NMR
 
(400 MHz, CDCl3į+V), 7.76 (2H, d, J = 8.0 Hz), 7.63 (1H, d, 
J = 9.0 Hz), 7.21 (1H, s), 7.20 ± 7.17 (2H, app m), 6.50 (1H, dd, J = 9.0, 2.5 Hz), 4.31 (2H, t, 
J = 9.5 Hz), 4.08 (2H, t, J = 9.5 Hz), 3.77 (3H, s), 2.34 (3H, s); 13C{1H} NMR
 
(100.6 MHz, 
CDCl3į3.7, 141.0, 137.0, 130.8, 129.6, 127.4, 108.8, 106.5, 102.8, 66.4, 
55.5, 54.4, 21.6; HRMS: m/z [MH]+ C17H19N2O4S calcd. 347.1060, found 347.1068. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-5-(trifluoromethyl)phenyl)-4-
methylbenzenesulfonamide (13). Following general procedure D, using p-toluenesulfonamide 
(34 mg, 0.20 mmol) and 2-(4-trifluoromethylphenyl)-4,5-dihydrooxazole (86 mg, 0.40 mmol) 
with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 
0.30 mmol)
 
in dichloromethane (2 mL) at 100 °C for 16 h, product 13 was isolated as a 
colorless solid (51 mg, 66%). M.p.: 160 ± 161 °C (dichloromethane/petroleum ether (40/60)); 
FTIR: vmax/ cm-1 (neat) 3089 (w), 2965 (w), 1646 (m), 1588 (m), 1522 (m), 1418 (s), 1321 (s), 
1253 (s), 1159 (s), 1121 (s), 1083 (s), 1063 (s), 959 (s); 1H NMR
 
(400 MHz, CDCl3į
(1H, s), 7.94 (1H, s), 7.85 (1H, d, J = 8.0 Hz), 7.77 (2H, d, J = 8.0 Hz), 7.25 ± 7.20 (3H, m), 
4.40 (2H, t, J = 9.5 Hz), 4.18 (2H, t, J = 9.5 Hz), 2.36 (3H, s); 13C{1H} NMR
 
(100.6 MHz, 
CDCl3įTJ = 33.0 Hz), 130.0, 129.7, 127.3, 123.3 (q, 
J = 273.0 Hz), 118.6 (d, J = 3.5 Hz), 115.9, 114.4 (d, J = 4.0 Hz), 66.7, 54.6, 21.5; 19F NMR 
(376.5 MHz; CDCl3į± 63.4; HRMS: m/z [MH]+ C17H16F3N2O3S calcd. 385.0828, found 
385.0834. 
Synthesis of N-(5-bromo-2-(4,5-dihydrooxazol-2-yl)phenyl)-4-methylbenzenesulfonamide 
(14). Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 2-
(4-bromophenyl)-4,5-dihydrooxazole (90 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 14 was isolated as a colorless solid (64 mg, 80%). M.p.: 142 
± 143 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 3051 (w), 2980 
(w), 1641 (s), 1593 (m), 1570 (m), 1489 (m), 1395 (m), 1357 (m), 1324 (s), 1256 (s), 1151 
(s), 1086 (s), 1060 (s), 936 (s); 1H NMR
 
(400 MHz, CDCl3į+V+GJ = 
2.0 Hz), 7.76 (2H, d, J = 8.0 Hz), 7.57 (1H, d, J = 8.5 Hz), 7.23 (2H, d, J = 8.0 Hz), 7.11 (1H, 
dd, J = 8.5, 2.0 Hz), 4.35 (2H, t, J = 9.5 Hz), 4.11 (2H, t, J = 9.5 Hz), 2.36 (3H, s); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3į164.2, 144.0, 140.2, 136.7, 130.6, 129.8, 127.3, 126.9, 125.5, 
120.6, 112.2, 66.7, 54.6, 21.7; HRMS: m/z [MH]+ C16H1679BrN2O3S calcd. 395.0060, found 
395.0063.  
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)phenyl)-3-(trifluoromethyl)benzenesulfonamide 
(18). Following general procedure D, using 3-(trifluoromethyl)benzenesulfonamide (45 mg, 
0.20 mmol) and 2-phenyl-2-oxazoline (59 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 18 was isolated as a colorless solid (61 mg, 83%). M.p.: 140 
± 141 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 3087 (w), 1639 
(m), 1588 (w), 1502 (m), 1433 (w), 1329 (s), 1279 (s), 1253 (s), 1154 (s), 1124 (s), 1103 (s), 
1068 (s); 1H NMR
 
(400 MHz, CDCl3į+V+V+GJ = 8.0 Hz), 
7.73 (2H, dd, J = 8.0, 1.5 Hz), 7.69 (1H, dd, J = 8.0, 1.0 Hz), 7.53 (1H, t, J = 8.0 Hz), 7.42 ± 
7.35 (1H, m), 7.06 (1H, td, J = 8.0, 1.0 Hz), 4.35 (2H, t, J = 9.0 Hz), 4.12 (2H, t, J = 9.0 Hz); 
13C{1H} NMR
 
(100.6 MHz, CDCl3 į T J = 33.5 Hz), 
130.5, 129.7, 129.6, 129.5 (q, J = 3.5 Hz), 124.4 (q, J = 4.0 Hz), 123.5, 123.3 (q, J = 273.0 
Hz), 119.0, 114.5, 66.7, 54.5; 19F NMR (376.5 MHz; CDCl3į± 62.9; HRMS: m/z [MH]+ 
C16H14F3N2O3S calcd. 371.0672, found 371.0676.  
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-4-methoxyphenyl)-2,2,2-trifluoroacetamide (19). 
Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 2-(3-
methoxyphenyl)-4,5-dihydrooxazole (43 mg, 0.24 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 19 was isolated as a colorless solid (12 mg, 20%). M.p.: 125 
± 126 °C (pentane); FTIR: vmax/ cm-1 (neat) 2975 (w), 1712 (m), 1601 (m), 1558 (m), 1372 
(m), 1276 (m), 1218 (m), 1131 (s), 1058 (s); 1H NMR
 
(400 MHz, CDCl3į0 (1H, s), 
8.60 (1H, d, J = 9.0 Hz), 7.40 (1H, d, J = 3.0 Hz), 7.05 (1H, dd, J = 9.0, 3.0 Hz), 4.42 (2H, t, 
J = 9.5 Hz), 4.15 (2H, t, J = 9.5 Hz), 3.82 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
164.5, 156.0, 155.2 (q, J = 37.5 Hz), 131.1, 121.8, 118.4, 116.2 (q, J = 288.5 Hz), 115.7, 
114.1, 66.8, 55.7, 54.6; 19F NMR (376.5 MHz; CDCl3 į ± 75.9; HRMS: m/z [MH]+ 
C12H12F3N2O3 calcd. 289.0795, found 289.0794.  
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-5-methoxyphenyl)-3-
(trifluoromethyl)benzenesulfonamide (21). Following general procedure D, using 3-
(trifluoromethyl)benzenesulfonamide (45 mg, 0.20 mmol) and 2-(3-methoxyphenyl)-4,5-
dihydrooxazole (71 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 
0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 100 °C for 16 
h, product 21 was isolated as a colorless solid (50 mg, 62%). M.p.: 152 ± 153 °C 
(dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 3081 (w), 2977 (w), 1644 
(m), 1610 (m), 1577 (m), 1514 (m), 1370 (m), 1319 (s), 1260 (m), 1154 (s), 1109 (s), 1061 
(s), 1035 (s); 1H NMR
 
(400 MHz, CDCl3į+V+V+GJ = 8.0 
Hz), 7.74 (1H, d, J = 8.0 Hz), 7.64 (1H, dd, J = 9.0 Hz), 7.55 (1H, t, J = 8.0 Hz), 7.22 (1H, d, 
J = 2.5 Hz), 6.56 (1H, dd, J = 9.0, 2.5 Hz), 4.33 (2H, t, J = 9.5 Hz), 4.09 (2H, t, J = 9.5 Hz), 
3.80 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3įTJ = 
33.5 Hz), 130.9, 130.5, 129.8, 129.5 (q, J = 3.5 Hz), 124.5 (q, J = 3.5 Hz), 123.3 (q, J = 273.0 
Hz), 109.7, 107.2, 103.8, 66.6, 55.6, 54.2; 19F NMR (376.5 MHz; CDCl3į± 62.9; HRMS: 
m/z [MH]+ C17H16F3N2O4S calcd. 401.0777, found 401.0784.  
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-5-(dimethylamino)phenyl)-2,2,2-
trifluoroacetamide (23). Following general procedure D, using trifluoroacetamide (23 mg, 
0.20 mmol) and 4-(4,5-dihydrooxazol-2-yl)-N,N-dimethylaniline (46 mg, 0.24 mmol) with 
[Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 
mmol)
 
in dichloromethane (2 mL) at 40 °C for 16 h, product 26 was isolated as a colorless 
solid (15 mg, 24%). M.p.: 132 ± 133 °C (pentane); FTIR: vmax/ cm-1 (neat) 2883 (w), 1710 
(m), 1616 (m), 1580 (m), 1535 (m), 1370 (s), 1238 (m), 1149 (s), 1121 (s), 1063 (s); 1H NMR
 
(400 MHz, CDCl3į13.84 (1H, s), 8.08 (1H, d, J = 2.5 Hz), 7.69 (1H, d, J = 9.0 Hz), 6.45 
(1H, dd, J = 2.5, 9.0 Hz), 4.35 (2H, t, J = 9.5 Hz), 4.08 (2H, t, J = 9.5 Hz), 3.05 (6H, s); 
13C{1H} NMR
 
(100.6 MHz, CDCl3į 165.1, 155.8 (app d, J = 37.5 Hz), 153.0, 139.0, 130.3, 
116.1 (app d, J = 288.5 Hz), 107.3, 103.0, 102.4, 66.4, 54.2, 40.2; 19F NMR
 
(376.5 MHz, 
CDCl3į± 76.0; HRMS: m/z [MH]+ C13H15F3N3O2 calcd. 302.1111, found 302.1111.  
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-4-(dimethylamino)phenyl)-2,2,2-
trifluoroacetamide (25). Following general procedure D, using trifluoroacetamide (23 mg, 
0.20 mmol) and 3-(4,5-dihydrooxazol-2-yl)-N,N-dimethylaniline (46 mg, 0.24 mmol) with 
[Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 
mmol)
 
in dichloromethane (2 mL) at 40 °C for 16 h, product 26 was isolated as an orange 
solid (8 mg, 12%). M.p.: 119 ± 120 °C (pentane); FTIR: vmax/ cm-1 (neat) 3006 (w), 2982 (w), 
1712 (m), 1597 (m), 1539 (m), 1264 (m), 1139 (s); 1H NMR
 
(400 MHz, CDCl3į13.32 (1H, 
s), 8.56 (1H, d, J = 9.0 Hz), 7.23 (1H, d, J = 2.5 Hz), 6.89 (1H, dd, J = 9.0, 2.5 Hz), 4.42 (2H, 
t, J = 9.5 Hz), 4.16 (2H, t, J = 9.5 Hz), 2.98 (6H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į 
164.8, 154.6 (app d, J = 37.0 Hz), 147.0, 127.6, 121.5, 116.3, 116.2 (app d, J = 288.5 Hz), 
115.3, 112.5, 66.6, 54.4, 40.7; 19F NMR
 
(376.5 MHz, CDCl3į± 75.8; HRMS: m/z [MH]+ 
C13H14F3N3O2 calcd. 302.1111, found 302.1115.  
Synthesis of 2,2,2-trifluoro-N-[2-(4-methoxyphenyl)-4,5-dihydro-oxazole]-acetamide (26)6. 
Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 2-(4-
methoxyphenyl)-4,5-dihydro-oxazole (71 mg, 0.400 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 40 °C for 16 h, product 26 was isolated as a colorless solid (57 mg, 100%). M.p.: 103 
± 104 °C (pentane); FTIR: vmax/ cm-1 (neat) 3117 (w), 2979 (w), 1714 (m), 1637 (m), 1181 
(s), 1145 (s); 1H NMR
 
(400 MHz, CDCl3į+V+G J = 2.5 Hz), 7.79 
(1H, d, J = 8.5 Hz), 6.73 (1H, dd, J = 8.5, 2.5 Hz), 4.39 (2H, t, J = 9.5 Hz), 4.12 (2H, t, J = 
9.5 Hz), 3.87 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3): į164.7, 162.9, 155.8 (q, J = 37.5 
Hz), 139.4, 130.6, 116.0 (q, J = 288.5 Hz), 111.0, 107.4, 105.3, 66.6, 55.7, 54.3;   19F NMR
 
(376.5 MHz, CDCl3 į ± 76.0; HRMS: m/z [MH]+ C12H12N2O3F3 calcd. 289.0800, found 
289.0799.  
Synthesis of 2,2,2-trifluoro-N-[2-(4-methylphenyl)-4,5-dihydro-oxazole]-acetamide (28)8. 
Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 4,5-
dihydro-2-(4-methylphenyl)-oxazole (65 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 40 °C for 16 h, product 28 was isolated as a colorless solid (46 mg, 84%). M.p.: 120 ± 
121 °C (pentane); FTIR: vmax/ cm-1 (neat) 3046 (w), 2958 (w), 1721 (s), 1637 (s), 1153 (s); 1H 
NMR
 
(400 MHz, CDCl3į+V+V+GJ = 8.0 Hz), 7.02 (1H, d, 
J = 8.0 Hz), 4.41 (2H, t, J = 9.5 Hz), 4.14 (2H, t, J = 9.5 Hz), 2.42 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3): 164.8, 155.6 (q, J = 37.5 Hz), 143.8, 137.5, 129.2, 125.3, 120.8, 116.1 
(q, J = 289.0 Hz), 112.0, 66.7, 54.4, 22.1; 19F NMR
 
(376.5 MHz, CDCl3į± 76.0; HRMS: 
m/z [MH]+ C12H12N2O2F3 calcd. 273.0851, found 273.0861. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-4-methylphenyl)-4-methylbenzenesulfonamide 
(29). Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 2-
(m-tolyl)-4,5-dihydrooxazole (65 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), 
AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 
100 °C for 16 h, product 29 was isolated as a colorless solid (31 mg, 47%). M.p.: 128 ± 129 
°C (pentane); FTIR: vmax/ cm-1 (neat) 2985 (w), 2914 (w), 1633 (s), 1514 (m), 1334 (s), 1253 
(s), 1152 (s), 1061 (s), 941 (m); 1H NMR
 
(400 MHz, CDCl3į+V+GJ 
= 8.0 Hz), 7.55 (1H, d, J = 8.5 Hz), 7.53 (1H, d, J = 1.5 Hz), 7.18 (2H, d, J = 8.0 Hz), 7.15 
(1H, dd, J = 8.5, 1.5 Hz), 4.33 (2H, t, J = 9.5 Hz), 4.11 (2H, t, J = 9.5 Hz), 2.34 (3H, s), 2.25 
(3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3 į      
129.7, 129.6, 127.3, 118.4, 113.8, 66.5, 54.6, 21.6, 20.7; HRMS: m/z [MH]+ C17H19N2O3S 
calcd. 331.1111, found 331.1116.  
Synthesis of 2,2,2-trifluoro-N-[2-(3-methylphenyl)-4,5-dihydro-oxazole]-acetamide (30)6. 
Following general procedure D, using trifluoroacetamide (65 mg, 0.20 mmol) and 2-(3-
methylphenyl)-4,5-dihydro-oxazole (104 mg, 0.400 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 40 °C for 16 h, product 30 was isolated as a colorless solid (39 mg, 72%). M.p.: 145 ± 
146 °C (pentane); FTIR: vmax/ cm-1 (neat) 3096 (w), 2993 (w), 2887 (w), 1714 (m), 1615 (m), 
1138 (s); 1H NMR
 
(400 MHz, CDCl3į+V+GJ = 8.5 Hz), 7.70 (1H, d, 
J = 2.0 Hz), 7.32 (1H, dd, J = 8.5, 2.0 Hz), 4.42 (2H, t, J = 9.5 Hz), 4.15 (2H, t, J = 9.5 Hz), 
2.36 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3įTJ = 288.5 Hz), 135.3, 
134.3, 133.4, 129.7, 120.3, 116.9 (q, J = 37.5 Hz), 114.4, 66.7, 54.5, 20.9; 19F NMR
 
(376.5 
MHz, CDCl3į± 76.0; HRMS: m/z [MH]+ C12H12N2O2F3 calcd. 273.0851, found 273.0859. 
Synthesis of methyl 4-(4,5-dihydrooxazol-2-yl)-3-(4-methylphenylsulfonamido)benzoate (31). 
Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and methyl 
4-(4,5-dihydrooxazol-2-yl)benzoate (82 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 31 was isolated as a colorless solid (55 mg, 73%). M.p.: 136 
± 137 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 3016 (w), 2990 
(w), 1720 (s), 1639 (s), 1578 (m), 1512 (m), 1327 (s), 1238 (s), 1157 (s), 1093 (s), 1063 (s), 
944 (s); 1H NMR
 
(400 MHz, CDCl3į+V+GJ = 1.5 Hz), 7.81 ± 7.75 
(3H, m),  7.63 (1H, dd, J = 8.0, 1.5 Hz), 7.22 (2H, d, J = 8.0 Hz), 4.38 (2H, t, J = 9.5 Hz), 
4.16 (2H, t, J = 9.5 Hz), 3.91 (3H, s), 2.35 (3H, s);  13C{1H} NMR
 
(100.6 MHz, CDCl3į
166.1, 164.1, 143.9, 139.3, 136.8, 133.5, 129.7, 129.6, 127.4, 123.1, 118.6, 116.9, 66.8, 54.7, 
52.6, 21.6; HRMS: m/z [MH]+ C18H19N2O5S calcd. 375.1009, found 375.1014.  
Synthesis of methyl 4-(4,5-dihydrooxazol-2-yl)-3-(2,2,2-trifluoroacetamido)benzoate (32). 
Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and methyl 4-
(4,5-dihydrooxazol-2-yl)benzoate (49mg, 0.24 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 mmol), 
AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 mL) at 
100 °C for 16 h, product 32 was isolated as a colorless solid (58 mg, 92%). M.p.: 129 ± 130 
°C (pentane); FTIR: vmax/ cm-1 (neat) 2982 (w), 2961 (w), 1733 (m), 1715 (m), 1588 (m), 
1297 (m), 1249 (s), 1158 (s), 1112 (s); 1H NMR
 
(400 MHz, CDCl3į + V
(1H, d, J = 1.5 Hz), 7.93 (1H, d, J = 8.0 Hz), 7.84 (1H, dd, J = 8.0, 1.5 Hz), 4.46 (2H, t, J = 
9.5 Hz), 4.18 (2H, t, J = 9.5 Hz), 3.94 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į
164.2, 155.7 (q, J = 38.0 Hz), 137.7, 133.9, 129.5, 125.4, 121.0, 117.8, 115.9 (q, J = 288.5 
Hz), 67.0, 54.6, 52.7; 19F NMR (376.5 MHz; CDCl3 į ± 76.1; HRMS: m/z [MH]+ 
C13H12F3N2O4 calcd. 317.0744, found 317.0746.   
Synthesis of methyl 3-(4,5-dihydrooxazol-2-yl)-4-(4-methylphenylsulfonamido)benzoate (33). 
Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and methyl 
3-(4,5-dihydrooxazol-2-yl)benzoate (82 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 33 was isolated as a colorless solid (43 mg, 57%). M.p.: 180 
± 181 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 3084 (w), 2957 
(w), 1710 (s), 1639 (s), 1593 (m), 1499 (m), 1438 (s), 1375 (m), 1339 (m), 1306 (s), 1281 (s), 
1154 (s) 929 (s); 1H NMR
 
(400 MHz, CDCl3į+V+GJ = 2.0 Hz), 7.98 
(1H, dd, J = 9.0, 2.0 Hz), 7.78 (2H, d, J = 8.0 Hz), 7.66 (1H, d, J = 9.0 Hz), 7.23 (2H, d, J = 
8.0 Hz), 4.41 (2H, t, J = 9.5 Hz), 4.17 (2H, t, J = 9.5 Hz), 3.86 (3H, s), 2.35 (3H, s); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3į
123.8, 116.7, 112.9, 66.8, 54.7, 52.3, 21.7; HRMS: m/z [MH]+ C18H19N2O5S calcd. 375.1009, 
found 375.1015.  
Synthesis of 2,2,2-trifluoro-N-[3-(4,5-dihydro-2-oxazolyl)-methyl ester benzoic acid]-
acetamide (34)6. Following general procedure D, using trifluoroacetamide (23 mg, 0.20 
mmol) and 3-(4,5-dihydro-2-oxazolyl)-methyl ester benzoic acid (104 mg, 0.400 mmol) with 
[Cp*RhCl2]2 (3 mg, 0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 
mmol)
 
in dichloromethane (2 mL) at 40 °C for 16 h, product 34 was isolated as a colorless 
solid (49 mg, 77%). M.p.: 212 ± 213 °C (pentane); FTIR: vmax/ cm-1 (neat) 2961 (w), 2891 
(w), 1715 (s), 1646 (m), 1594 (m), 1155 (s), 1139 (s), 767 (s); 1H NMR
 
(400 MHz, CDCl3į
13.90 (1H, s), 8.74 (1H, d, J = 9.0 Hz), 8.57 (1H, d, J = 2.0 Hz), 8.17 (1H, dd, J = 9.0, 2.0 
Hz), 4.47 (2H, t, J = 9.5 Hz), 4.19 (2H, t, J = 9.5 Hz), 3.93 (3H, s); 13C{1H} NMR
 
(100.6 
MHz, CDCl3 į    T J = 38.0 Hz), 141.3, 134.0, 131.1, 126.2, 120.1, 
116.4 (q, J = 288.5 Hz), 114.5, 67.0, 54.6, 52.4; 19F NMR
 
(376.5 MHz, CDCl3į± 76.0; 
HRMS: m/z [MH]+ C13H12N2O4F3 calcd. 317.0744, found 317.0743. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-5-fluorophenyl)-4-methylbenzene sulfonamide 
(35). Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 2-
(4-fluorophenyl)-4,5-dihydrooxazole (66 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 35 was isolated as a colorless solid (48 mg, 72%). M.p.: 145 
± 146 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 2985 (w), 2914 
(w), 1644 (s), 1598 (s), 1509 (s), 1423 (m), 1367 (s), 1329 (s), 1276 (s), 1261 (s), 1147 (s), 
1058 (s); 1H NMR
 
(400 MHz, CDCl3į+V± 7.75 (2H, app m), 7.72 (1H, 
dd, J = 9.0, 6.5 Hz), 7.39 (1H, dd, J = 11.0, 2.5 Hz), 7.23 (2H, d, J = 8.0 Hz), 6.67 (1H, ddd, 
J = 9.0, 8.0, 2.5 Hz), 4.36 (2H, t, J = 9.5 Hz), 4.12 (2H, t, J = 9.5 Hz), 2.36 (3H, s); 13C{1H} 
NMR
 
(100.6 MHz, CDCl3įGJ = 252.0 Hz), 164.1, 144.0, 141.4 (d, J = 12.0 Hz), 
136.8, 131.5 (d, J = 10.5 Hz), 129.8, 127.3, 109.7 (d, J = 2.5 Hz), 109.5 (d, J = 22.0 Hz), 
105.0 (d, J = 27.5 Hz) 66.6, 54.5, 21.6; 19F NMR (376.5 MHz; CDCl3į± 104.1; HRMS: 
m/z [MH]+ C16H16FN2O3S calcd. 336.0890, found 336.0893.  
Synthesis of 2,2,2-trifluoro-N-[2-(4-fluorophenyl)-4,5-dihydro-oxazole]-acetamide (36)6. 
Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 2-(4-
fluorophenyl)-4,5-dihydro-oxazole (66 mg, 0.400 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 40 °C for 16 h, product 36 was isolated as a colorless solid (54 mg, 97%). M.p.: 121 ± 
122 °C (pentane); FTIR: vmax/ cm-1 (neat) 3124 (w), 2993 (w), 1721 (m), 1637 (m), 1142 (s), 
757 (s); 1H NMR
 
(400 MHz, CDCl3į+V+GGJ = 11.0, 2.5 Hz), 7.89 
(1H, dd, J = 9.0, 7.0 Hz), 6.91 (1H, ddd, J = 9.0, 7.0, 2.5 Hz), 4.43 (2H, t, J = 9.5 Hz), 4.15 
(2H, t, J = 9.5 Hz); 13C{1H} NMR
 
(100.6 MHz, CDCl3įGJ = 57. 0 Hz), 
155.9 (q, J = 37.5 Hz), 139.5 (d, J = 12.0 Hz), 131.3 (d, J = 10.5 Hz), 115.1 (q, J = 288.5 Hz), 
111.7 (d, J = 22.0 Hz), 110.9, 108.2 (d, J = 28.5 Hz), 66.9, 54.4; 19F NMR
 
(376.5 MHz, 
CDCl3 į ± 76.1, ± 103.3; HRMS: m/z [MH]+ C11H9N2O2F4 calcd. 277.0600, found 
277.0601. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-6-fluorophenyl)-4-methylbenzenesulfonamide 
(37). Following general procedure D, using p-toluenesulfonamide (34 mg, 0.20 mmol) and 2-
(3-fluorophenyl)-4,5-dihydrooxazole (66 mg, 0.40 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 37 was isolated as a colorless solid (40 mg, 61%). M.p.: 109 
± 110 °C (dichloromethane/petroleum ether (40/60)); FTIR: vmax/ cm-1 (neat) 3071 (w), 2980 
(w), 2962 (w), 1639 (m), 1473 (s), 1449 (s), 1327 (s), 1268 (s), 1152 (s), 1088 (s), 991 (s); 1H 
NMR
 
(400 MHz, CDCl3į+V+GJ = 8.0 Hz), 7.55 (1H, d, J = 8.0 Hz), 
7.26 (2H, d, J = 8.0 Hz), 7.21 ± 7.14 (1H, m), 7.08 (1H, td, J = 8.0, 5.0 Hz), 4.30 (2H, t, J = 
9.5 Hz), 4.05 (2H, t, J = 9.5 Hz), 2.41 (3H, s); 13C{1H} NMR
 
(100.6 MHz, CDCl3į 
(d, J = 3.5 Hz), 155.5 (d, J = 250.0 Hz), 143.4, 138.1, 129.2, 127.7 (d, J = 14.0 Hz), 127.3 (d, 
J = 1.5 Hz), 124.7 (d, J = 3.0 Hz), 124.7 (d, J = 3.0 Hz), 119.9 (d, J = 20.5 Hz), 119.3 (d, J = 
3.5 Hz), 66.8, 54.6, 21.7; 19F NMR (376.5 MHz; CDCl3 į ± 115.7; HRMS: m/z [MH]+ 
C16H16FN2O3S calcd. 335.0860, found 335.0866. 
Synthesis of N-(2-(4,5-dihydrooxazol-2-yl)-6-fluorophenyl)-2,2,2-trifluoroacetamide (38). 
Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 2-(3-
fluorophenyl)-4,5-dihydrooxazole (40 mg, 0.24 mmol) with [Cp*RhCl2]2 (3 mg, 0.005 
mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in dichloromethane (2 
mL) at 100 °C for 16 h, product 38 was isolated as a colorless solid (33 mg, 60%). M.p.: 119 
± 120 °C (pentane); FTIR: vmax/ cm-1 (neat) 1742 (s), 1644 (m), 1532 (s), 1532 (s), 1474 (s), 
1362 (s), 1271 (s), 1205 (s), 1129 (s); 1H NMR
 
(400 MHz, CDCl3į+V+
dd, J = 7.0, 2.0 Hz), 7.36 ± 7.27 (2H, m), 4.44 (2H, t, J = 9.5 Hz), 4.15 (2H, t, J = 9.5 Hz); 
13C{1H} NMR
 
(100.6 MHz, CDCl3įGJ = 3.5 Hz), 155.7 (d, J = 254.5 Hz), 154.9 
(q, J = 38.0 Hz), 126.9 (d, J = 8.0 Hz), 124.8 (d, J = 3.0 Hz), 124.0 (d, J = 14.5 Hz), 120.3 (d, 
J = 3.5 Hz), 120.2 (d, J = 20.5 Hz), 116.1 (q, J = 287.0 Hz), 67.1, 54.8; 19F NMR (376.5 
MHz; CDCl3 į ± 75.5, - 111.0; HRMS: m/z [MH]+ C11H9F4N2O2 calcd. 277.0595, found 
277.0596.  
Synthesis of N-(6-chloro-4-(4,5-dihydrooxazol-2-yl)pyridine-3-yl)-2,2,2-trifluoroacetamide 
(45).7 Following general procedure D, using trifluoroacetamide (23 mg, 0.20 mmol) and 2-(2-
chloropyridin-4-yl)-4,5-dihydrooxazole 44 (44 mg, 0.24 mmol) with [Cp*RhCl2]2 (3 mg, 
0.005 mmol), AgSbF6 (7 mg, 0.02 mmol) and PhI(OAc)2 (97 mg, 0.30 mmol) in 
dichloromethane (2 mL) at 40 °C for 20 h, product 45 was isolated as a colourless solid (34 
mg, 58%). M.p.: 98 ± 99 °C; FTIR: vmax/ cm-1 (neat) 3097 (w), 2921 (w), 2882 (w), 1726 (s), 
1589 (m), 1565 (m), 1522 (m), 1307 (s), 1143 (s), 1123 (s), 944 (s), 741 (s); 1H NMR
 
(400 
MHz, CDCl3į+V1H), 9.73 (1H, s, CHar), 7.75 (1H, s, CHar), 4.51 (2H, t, J = 9.5 
Hz, CH2), 4.24 (2H, t, J = 9.5 Hz, CH2); 19F NMR (376.5 MHz, CDCl3į± 75.8; 13C{1H} 
NMR
 
(100.6 MHz, CDCl3 į   T J = 38.5 Hz), 147.1, 142.4, 132.2, 123.4, 
122.9, 115.7 (q, J = 288.5 Hz), 67.6, 54.8; HRMS: m/z [MH]+ C10H835ClF3N3O2 calcd. 
294.0252, found 294.0252. 
Synthesis of 6-chloro-4-(4,5-dihydrooxazol-2-yl)pyridin-3-amine.7 To a round bottomed flask 
was added N-(6-chloro-4-(4,5-dihydrooxazol-2-yl)pyridine-3-yl)-2,2,2-trifluoroacetamide 45 
(680 mg, 2.31 mmol) and methanol (23 mL). NaOH pellets (277 mg, 6.93 mmol) were then 
added and the reaction mixture was stirred at room temperature for 18 hours. The reaction 
mixture was concentrated, dissolved in ethyl acetate and deionised water and transferred to a 
separating funnel. The layers were partitioned and the aqueous layer was further extracted 
with ethyl acetate. The combined organic layers were dried over anhydrous MgSO4, filtered 
and the solvent was removed in vacuo to afford the aniline product as colourless solid (364 
mg, 80%). M.p.: 184 ± 185 °C; FTIR: vmax/ cm-1 (neat) 3347 (w), 3151 (w), 2980 (w), 1643 
(m), 1614 (m), 1475 (s), 1364 (s), 1290 (m), 1247 (m), 1111 (m), 951 (s), 869 (s); 1H NMR
 
(400 MHz, d6-'062į+V&Har), 7.37 (1H, s, CHar), 7.11 (2H, s, NH2), 4.36 (2H, 
t, J = 9.5 Hz, CH2), 4.07 (2H, t, J = 9.5 Hz, CH2); 13C{1H} NMR (100.6 MHz, d6-'062į
162.0, 144.0, 138.8, 135.0, 121.6, 115.6, 66.7, 55.3; HRMS: m/z [MH]+C8H935ClN3O calcd. 
198.0429, found 198.0428. 
Synthesis of ethyl 5-amino-2-chloroisonicotinate (46). To a round bottomed flask equipped 
with a reflux condenser was added 6-chloro-4-(4,5-dihydrooxazol-2-yl)pyridin-3-amine (50 
mg, 0.25 mmol) followed by ethanol (6.3 mL) and concentrated H2SO4 (0.7 mL). The 
reaction mixture was stirred and heated at reflux for 20 h. The reaction was then allowed to 
cool to room temperature and diluted with water. The reaction mixture was then neutralised 
to pH 6 using a saturated aqueous solution of NaHCO3 and transferred to a separating funnel 
with ethyl acetate. The layers were partitioned and the aqueous layer was further extracted 
with ethyl acetate. The combined organic layers were then dried over anhydrous MgSO4, 
filtered and the solvent was removed in vacuo. The residue was purified by flash column 
chromatography on silica gel, eluting with petroleum ether (40/60) and ethyl acetate (0% to 
40% ethyl acetate) to afford the ester product 46 as an orange amorphous solid (20 mg, 40%). 
FTIR: vmax/ cm-1 (neat) 2989 (w), 1701 (m), 1274 (m), 767 (s); 1H NMR (400 MHz, CDCl3): 
į± 7.96 (1H, m, CHar), 7.66 ± 7.65 (1H, m, CHar), 5.12 (2H, br s, NH2), 4.37 (2H, q, J = 
7.0 Hz, CH2), 1.40 (3H, t, J = 7.0 Hz, CH3); 13C{1H} NMR (100.6 MHz, CDCl3į
143.9, 139.9, 137.9, 123.5, 119.0, 61.7, 14.3; HRMS: m/z [MH]+ C8H1035ClN2O2 calcd. 
201.0425, found 201.0429. 
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